アロステリック HECT E3 リガース阻害の治療的可能性
Alexander M K Rothman1, Amir Florentin2, Florence Zink3
1University of Sheffield, Sheffield, UK; Novartis BioMedical Research (NBR), Cambridge, MA, USA.
Cell
|April 3, 2025
まとめ
研究者らは,特にSMURF1の謎の穴を標的とした,ユビキチンE3リガゼの新種の阻害剤を発見した. この発見は,BMPR2シグナリングを調節することによって,肺動脈高血圧 (PAH) の新しい治療戦略を提供します.
科学分野:
- 生物化学
- 分子生物学
- 薬理学について
背景:
- ユビキチンE3リガスは魅力的な治療標的ですが,活性サイトポケットの欠如は阻害剤の開発を妨げます.
- E6関連タンパク質C末端 (HECT) と同型であるE3リガスは,そのユニークな触媒メカニズムのために課題を提示する.
- 肺動脈高血圧 (PAH) は,HECT E3リガゼであるSMURF1のレベル上昇と関連しています.
研究 の 目的:
- SMURF1を中心に,HECT E3リガスの新しい阻害剤を特定する.
- 特定された阻害剤の作用機構を明らかにする.
- PAHにおけるSMURF1抑制の治療の可能性を調査する.
主な方法:
- SMURF1阻害剤を特定するための大規模な偏見のない生化学的スクリーニング.
- 阻害剤の結合とメカニズムを決定するための構造的および生化学的分析.
- HECT E6AP阻害剤のシリコン機械学習ベースのスクリーニング
- 治療効果を評価するためのPAHの実験モデル
主要な成果:
- SMURF1の触媒部位とは異なる暗号腔に結合する阻害物質が発見されました.
- 阻害剤は,グリシンヒンジとのα-ヘリックス相互作用を通じて触媒運動を制限することによって機能します.
- 実験的なPAHにおけるSMURF1阻害は,BMPシグナル伝達を正常化し,血管ホメオスタシスを回復し,病理を逆転させた.
- HECT E6AP阻害剤では,グリシンヒンジ依存性アロステリック活性が確認された.
結論:
- グリシンヒンジのような神秘的なアロステリック部位を標的にすることは,HECT E3リガスを抑制する有効な戦略です.
- SMURF1の抑制は,PAHの治療の可能性を示しています.
- このアプローチは,HECT E3リガゼおよび関連するタンパク質のための薬剤可能な空間を拡大します.
さらに関連する動画
08:45Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
6.1K
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
関連する概念動画
Allosteric Regulation
57.4K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.4K
Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K
Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K
Feedback Inhibition
53.5K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
53.5K
Cooperative Allosteric Transitions
7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K
Amplifying Signals via Enzymatic Cascade
8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K
